Jones, Aksana
Saini, Jay
Kriel, Belinda
Via, Laura E.
Cai, Yin
Allies, Devon
Hanna, Debra
Hermann, David
Loxton, Andre G.
Walzl, Gerhard
Diacon, Andreas H.
Romero, Klaus
Higashiyama, Ryo
Liu, Yongge
Berg, Alexander
Funding for this research was provided by:
Bill and Melinda Gates Foundation
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Otsuka Pharmaceutical
Article History
Received: 22 December 2021
Accepted: 9 March 2022
First Online: 2 April 2022
Declarations
:
: All methods were carried out in accordance with relevant guidelines and regulations.All studies reported herein received ethics approval. The following Institutional Review Boards (IRBs)/Ethics Committees approved the Kawasaki study cohorts [CitationRef removed]: Tropic Disease Foundation Institutional Review Board, Lung Center Ethics Review Committee, Jose R. Reyes Memorial Medical Center Institutional Review Board, and The Medical City Institutional Review Board, all in Manila, Philippines. The following IRBs / Ethics Committees approved the NexGen EBA study [CitationRef removed]: National Institute of Allergy and Infectious Diseases Institutional Review Board (initial review and study conduct), National Institutes of Health Institutional Review Board (oversight for data/specimen analysis only), Stellenbosch University Health Research Ethics Committee, and South African Health Products Regulatory Authority.All study participants reviewed and signed the informed consent form.
: Not applicable.
: AB, AGL, AHD, AJ, BK, DA, DH, DHe, JS, KR, LEV, RH, YC, and YL have no competing interests.GW holds the following 3 patents:Method for diagnosing tuberculosis: AP/P/2016/009427 (ARIPO), 201580023042.X (China), 15755681.2 (Europe), 201617030869 (India), F/P/2016/258 (Nigeria), 2016/06324 (South Africa).Serum host biomarkers for tuberculosis disease: PCT/IB2017/052142, due for national filing.TB diagnostic markers: PCT/IB2013/054377 (USA), host markers in whole blood culture supernatants.